Vaccine Advisory Panel Resumes Deliberation Over J&J COVID Vaccine Pause

ORLANDO, FLORIDA, UNITED STATES - 2021/04/10: Johnson & Johnson COVID-19 vial and box seen at a vaccination site.Doses of the Johnson & Johnson vaccine are being administered throughout the state of Florida despite a small number of patients who have experienced adverse reactions, including blood clots. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)
Johnson & Johnson COVID-19 vaccine vial and box. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)
|
April 23, 2021 4:17 p.m.

A federal vaccine advisory committee continued its deliberations on Friday over whether or not it should lift its recommendation for a pause on administering doses of Johnson & Johnson’s single-shot coronavirus vaccine. The pause was issued after reports earlier this month that six women developed a life-threatening blood-clotting condition after getting the vaccine in recent weeks.

If lifted, the Centers for Disease Control and Prevention and the Federal Drug Administration could recommend that public health officials resume administering the roughly 9 million doses that have already been distributed to states within hours or days — although any advisory panel recommendation would need to be approved by CDC director Rochelle Walensky.

Ahead of Friday’s meeting, the FDA was expected to lift the pause given that experts have said the risk of developing a clot after receiving the vaccine appears far lower than the chance of a clotting issue caused by a severe COVID-19 infection. The CDC says there have been 7 cases of the complication per million doses among women between 18 and 49.

Two government officials familiar with the matter told the Washington Post that the panel is expected to recommend attaching a warning to the vaccine’s label to inform vaccinators and potential vaccine recipients about the rare and dangerous possible side effect, without imposing age restrictions. The vaccine doses could be used again as soon as this weekend, they said.

Newsletters
Get TPM in your inbox, twice weekly.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

The committee’s considerations comes as the CDC reported on Friday nine new cases of a rare blood-clotting disorder in people who had received Johnson & Johnson’s COVID-19 vaccine, bringing the tally of those known to have developed the extremely rare complication to 15, four of whom are currently in an intensive care unit.

The new data was presented at a meeting of the agency’s independent Advisory Committee on Immunization Practices, after the panel said last week that it needed more information before it could determine just how low the risk was for developing the blood-clotting issue. 

The 15 cases were a scattered few among nearly 8 million doses of the vaccine administered as of April 21.

All of the confirmed cases reported were in women, including three who died and seven who remain in the hospital, although CDC officials have cautioned that any conclusions that only women were affected by the disorder would be premature.

“We know that it’s not a good thing to leave the pause going for any longer than it absolutely has to go for,” Dr. Peter Marks, a top FDA vaccine regulator, told The New York Times on Thursday. “Once, essentially, the adequate discussion has occurred, we’re prepared to move as quickly as we possibly can.”

Latest News
Comments are now Members-Only

Non-members are still able to read comments, but will no longer be able to participate. To join the conversation, sign up now and get:

30% Off Annual Prime Membership

TPM strives to build as inclusive a community as financially possible. We offer FREE memberships to those experiencing financial hardship and FREE memberships for students.

View all options
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: